Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
EA4151
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
- NCT03267433 ↗
- Active, not recruiting
- ECOG-ACRIN Cancer Research Group
- Deep
We haven't built an HCP commentary report on EA4151 (rituximab and hyaluronidase human and rituximab in Mantle Cell Lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EA4151 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 17 | |
| YouTube | 16 | |
| Podcasts | 6 | |
| Bluesky threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Bone Marrow Aspirate; Bone Marrow Biopsy; Computed Tomography; Positron Emission Tomography; Rituximab; Rituximab and Hyaluronidase Human
- Arms
- Group I (auto-HCT, rituximab) · Experimental
- Group II (rituximab) · Experimental
- Enrollment
- 689 (estimated)
- Primary outcomes
- Overall survival (OS) in mantle cell lymphoma (MCL) patients in minimal residual disease (MRD)-negative complete remission (CR) who undergo auto-hematopoietic stem cell transplant (HCT) followed by rituximab versus (vs.) maintenance rituximab alone
- Sponsor
- ECOG-ACRIN Cancer Research Group with National Cancer Institute (NCI)
- Start
- Nov 27, 2017
- Primary completion
- Jan 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03267433 · updated Sep 14, 2026
Publications
linked from the registry- Kumar A. What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma? Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):155-162. doi: 10.1182/hematology.2022000333. PubMed 36485104
- Thiruvengadam SK, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T 3rd, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):246-256.e2. doi: 10.1016/j.clml.2020.11.005. Epub 2020 Nov 11. PubMed 33288485